Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price objective increased by Chardan Capital from $20.00 to $31.00 in a research report sent to investors on Friday morning, Stock Target Advisor reports. Chardan Capital currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on the stock. […]
Jasper Therapeutics (NASDAQ:JSPR) Receives Outperform Rating from Oppenheimer theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Wedbush reaffirmed their outperform rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $17.00 price objective on the biotechnology company’s stock. Wedbush also issued estimates for Astria Therapeutics’ Q1 2024 earnings at ($0.36) EPS, Q2 2024 earnings at […]
Dyne Therapeutics (DYN) Outperform Rating Reiterated at Oppenheimer theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews com Downgrades MediWound (NASDAQ:MDWD) to Sell theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.